XML 25 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

9.

Commitments and Contingencies


Our Company conducts its operations in leased facilities under a non-cancelable operating lease expiring in 2024.


Due to the adoption of the new lease standard under the optional transition method which allows the entity to apply the new lease standard at the adoption date, our Company has capitalized the present value of the minimum lease payments commencing January 1, 2019, using an estimated incremental borrowing rate of 6%. The minimum lease payments do not include common area annual expenses which are considered to be non-lease components.


As of January 1, 2019 the operating lease right-of-use asset and operating lease liability amounted to $241,100 with no cumulative-effect adjustment to the opening balance of accumulated deficit.


There are no other material operating leases. Our Company has elected not to recognize right-of-use assets and lease liabilities arising from short-term leases.


Future minimum lease payments under non-cancelable operating leases with initial or remaining terms of one year or more at December 31, 2020 are: $53,100 – 2021; $54,600 – 2022; $56,200 – 2023 and $18,900 – 2024.


Total lease expense under operating leases was $53,300 in each of the years ended December 31, 2020 and December 31, 2019.


Maturities of lease liabilities are as follows:


 

 

 

 

 

Operating Leases

 

Year ending December 31

 

 

 

 

 

 

 

2021

 

 

 

 

$

53,100

 

2022

 

 

 

 

 

54,600

 

2023

 

 

 

 

 

56,200

 

2024

 

 

 

 

 

18,900

 

Total lease payments

 

 

 

 

 

182,800

 

Less imputed interest

 

 

 

 

 

(22,500

)

Total

 

 

 

 

$

160,300

 


Our Company has an employment agreement, expiring in May 2022, with Michael A. Feinstein, M.D., its Chairman of the Board and Chief Executive Officer. The employment agreement contains one-year renewal provisions that became effective after the original term. Dr. Feinstein receives base compensation of $120,000 per year effective January 1, 2020 plus a performance bonus determined by our Company’s Board of Directors. Our Company has an employment agreement, expiring in March 2022, with Terry W. Stovold, its Chief Operating Officer, whereby Mr. Stovold receives a salary set by our Company’s Board of Directors, currently set at $75,000, along with a commission of seven percent on sales generated by his efforts. The employment agreement contains one-year renewal provisions that became effective after the original term. Future minimum compensation payments under these employment agreements are: $195,000 to be paid in 2021 and $68,800 to be paid in 2022.


From time to time, our Company may be subject to legal proceedings and claims that arise in the ordinary course of its business.